Liquid Biopsy · @Liquid_Biopsy
24th Dec 2014 from TwitLonger
for what its worth: $CYCC email reply to investors (unconfirmed) Thank you for your email. We share your surprise and disappointment in the outcome of the interim analysis for futility of the SEAMLESS study. In compliance with US securities laws, we can only comment on facts that have been previously disclosed in a public communication. This cannot include supposition or speculation. The examples of other companies offered have little similarity to our circumstances. As management and the Board of Directors evaluate any changes in strategy and operating plans, rest assured we will be updating investors consistently with the company’s past practice.
The key message with regard to the SEAMLESS study, is that management and the Board of Directors elected to accept the DSMB’s recommendation to follow up recruited patients to the final analysis in case the study produces a favorable final outcome that could be discussed with regulatory authorities. Final analysis is estimated to occur between 2H 2015 and 1H 2016. The company has adequate financial resources to reach beyond this period. Over the next few weeks during the JP Morgan and the BIO CEO investor conferences we will be reinforcing these messages.
We appreciate your interest in Cyclacel and our sapacitabine AML program.
Best regards,
Paul